4D Molecular Therapeutics (FDMT) EBIT (2020 - 2026)
4D Molecular Therapeutics (FDMT) posted quarterly EBIT of -$73.6 million for Q1 2026, down 37.3% year-over-year from -$117.4 million in Q1 2025, and down 600.31% quarter-over-quarter from $14.7 million in Q4 2025.
4D Molecular Therapeutics (FDMT) EBIT (2020 - 2026) Analysis & Trends
4D Molecular Therapeutics (FDMT) has reported EBIT for 7 consecutive years, with -$73.6 million the latest figure, recorded in Q1 2026.
- In Q1 2026, EBIT fell 37.3% year-over-year to -$73.6 million; the TTM figure through Mar 2026 stood at -$179.5 million (up 11.7% YoY), while the FY2025 annual figure was -$159.5 million, up 15.06% from the prior year.
- EBIT declined to -$73.6 million in Q1 2026 per FDMT's latest filing, from $14.7 million in the prior quarter.
- Across five years, EBIT topped out at $14.7 million in Q4 2025 and bottomed at -$73.6 million in Q1 2026.
- Historically, EBIT has averaged -$37.9 million across 5 years, with a median of -$36.7 million in 2023.
- Annual changes were most pronounced in 2022 — EBIT sank 274.22% — and 2025, when it surged 126.22%.
- 4D Molecular Therapeutics' EBIT stood at -$28.7 million in 2022, then declined by 27.62% to -$36.7 million in 2023, then tumbled by 53.11% to -$56.1 million in 2024, then soared by 126.22% to $14.7 million in 2025, then plunged by 600.31% to -$73.6 million in 2026.
- Business Quant data shows FDMT's EBIT at -$73.6 million in Q1 2026, $14.7 million in Q4 2025, and -$61.2 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 493.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -505.13 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 325.05 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -3,158.03 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 133.12 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 231.44 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -1.55 Mn |
| 10 | 4D Molecular Therapeutics | 856.62 Mn | 495.28 Mn | - | -77.03 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -77.03 Mn |
| Mar 31, 2026 | -73.62 Mn |
| Dec 31, 2025 | 14.72 Mn |
| Sep 30, 2025 | -61.19 Mn |
| Jun 30, 2025 | -59.46 Mn |
| Mar 31, 2025 | -53.62 Mn |
| Dec 31, 2024 | -56.12 Mn |
| Sep 30, 2024 | -51.13 Mn |
| Jun 30, 2024 | -42.46 Mn |
| Mar 31, 2024 | -38.14 Mn |
| Dec 31, 2023 | -36.65 Mn |
| Sep 30, 2023 | -13.97 Mn |
| Jun 30, 2023 | -32.14 Mn |
| Mar 31, 2023 | -30.11 Mn |
| Dec 31, 2022 | -28.72 Mn |
| Sep 30, 2022 | -26.50 Mn |
| Jun 30, 2022 | -28.43 Mn |
| Mar 31, 2022 | -26.39 Mn |
| Dec 31, 2021 | -24.76 Mn |
| Sep 30, 2021 | -22.66 Mn |